We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the use of gepants and their impact on the treatment landscape for migraines.
The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- Could you give us a brief overview of the new generation of gepants and their impact on the treatment landscape for migraines? (0:18)
- How does the efficacy and safety of gepants compare with antibody-based calcitonin gene-related peptide (CGRP) antagonists? (1:57)
- What are the advantages of atogepant and what have we learned about its efficacy and safety to date? (4:26)
Disclosures: Jessica Ailani has been an independent consulting (received honoraria) for Amgen, Abbvie, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Teva, Impel, Satsuma, Axsome, Vorso, Aeon, Theranica, Medscape; and has ownership of Stocks in CtrM; and is on part of the Speakers Bureau, and received honoraria for promotional speaking from Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva; and has provided editorial services (Honoraria) to Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, Infomedica (AHS Virtual Highlights 2020), SELF (medical reviewer). Jessica Ailani has also received Clinical Trial grants from (Fees to Institution) American Migraine Foundation, Allergan/Abbvie, Biohaven, Eli Lilly and Company, Satsuma and Zosano.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
